Alignment Healthcare (NASDAQ:ALHC) Insider Robert Scavo Sells 69,541 Shares of Stock

Alignment Healthcare, Inc. (NASDAQ:ALHC) insider Robert Scavo sold 69,541 shares of the company’s stock in a transaction dated Monday, December 29th. The stock was sold at an average price of $18.74, for a total value of $1,303,198.34. Following the transaction, the insider directly owned 503,014 shares of the company’s stock, valued at approximately $9,426,482.36. This represents a 12.15% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Alignment Healthcare Price Performance

Shares of NASDAQ ALHC opened at $19.24 on Wednesday. The stock’s 50-day simple moving average is $18.22 and its 200-day simple moving average is $16.22. The firm has a market capitalization of $3.85 billion, a PE ratio of -160.33 and a beta of 1.16. Alignment Healthcare, Inc. has a fifty-two week low of $11.01 and a fifty-two week high of $21.06. The company has a debt-to-equity ratio of 1.99, a quick ratio of 1.61 and a current ratio of 1.61.

Alignment Healthcare (NASDAQ:ALHC) last announced its quarterly earnings results on Thursday, October 30th. The company reported $0.02 EPS for the quarter, beating the consensus estimate of ($0.01) by $0.03. Alignment Healthcare had a negative net margin of 0.57% and a negative return on equity of 16.23%. The company had revenue of $993.70 million for the quarter, compared to analyst estimates of $980.90 million. During the same period in the prior year, the firm posted ($0.14) earnings per share. The firm’s revenue was up 43.5% on a year-over-year basis. As a group, equities research analysts forecast that Alignment Healthcare, Inc. will post -0.69 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on ALHC. JPMorgan Chase & Co. raised their price objective on Alignment Healthcare from $20.00 to $23.00 and gave the stock an “overweight” rating in a report on Wednesday, December 17th. Wall Street Zen upgraded Alignment Healthcare from a “hold” rating to a “buy” rating in a research note on Saturday, November 8th. KeyCorp reiterated an “overweight” rating on shares of Alignment Healthcare in a research note on Monday, November 24th. The Goldman Sachs Group restated a “buy” rating and set a $22.00 target price on shares of Alignment Healthcare in a research report on Monday, November 3rd. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Alignment Healthcare in a research report on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $20.35.

Hedge Funds Weigh In On Alignment Healthcare

A number of hedge funds and other institutional investors have recently bought and sold shares of ALHC. Larson Financial Group LLC purchased a new position in Alignment Healthcare during the 3rd quarter worth $33,000. SBI Securities Co. Ltd. increased its stake in shares of Alignment Healthcare by 4,868.9% during the second quarter. SBI Securities Co. Ltd. now owns 3,031 shares of the company’s stock worth $42,000 after acquiring an additional 2,970 shares during the period. KBC Group NV purchased a new position in Alignment Healthcare during the second quarter worth about $44,000. Signaturefd LLC lifted its position in Alignment Healthcare by 142.6% in the second quarter. Signaturefd LLC now owns 3,768 shares of the company’s stock valued at $53,000 after purchasing an additional 2,215 shares during the period. Finally, Wilmington Savings Fund Society FSB purchased a new stake in Alignment Healthcare in the 3rd quarter valued at approximately $53,000. 86.19% of the stock is currently owned by hedge funds and other institutional investors.

Key Stores Impacting Alignment Healthcare

Here are the key news stories impacting Alignment Healthcare this week:

• Positive Sentiment: Baird published a note saying Alignment Healthcare “should be bought on recent selloff,” which can attract value-oriented buyers and help lift the stock. Baird Buy Note
• Negative Sentiment: CEO John E. Kao sold 605,648 shares at an average price of $18.74 (~$11.35M), a 21.33% reduction in his holding — a large, high‑profile insider sale that can be read as a negative signal for sentiment. Kao SEC Filing
• Negative Sentiment: President Dawn Christine Maroney sold 282,070 shares at $18.74 (~$5.29M), cutting her stake by ~16.9% — another sizable insider disposition that can weigh on investor confidence. Maroney SEC Filing
• Negative Sentiment: Other insider sales include Robert L. Scavo (69,541 shares), Christopher J. Joyce (16,187 shares) and Hyong Kim (12,694 shares), each sold at $18.74 — smaller individually but collectively add to the sell-side signal. Scavo SEC Filing Joyce SEC Filing Kim SEC Filing

Alignment Healthcare Company Profile

Alignment Healthcare, Inc (NASDAQ: ALHC) is a health care company specializing in value-based care for Medicare Advantage beneficiaries. The company leverages an integrated care model that combines in-home clinical services, telehealth capabilities and digital health tools to manage chronic conditions, improve outcomes and enhance patient experience.

At the core of Alignment Healthcare’s approach is a proprietary technology platform that aggregates real-time clinical and claims data to support preventive care, risk stratification and personalized care plans.